Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy.
Burnett
Arthur L
AL
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD 21287-2411, USA.
D000368:Aged; D001341:Autonomic Nervous System / Q000293:injuries / Q000502:physiology / Q000601:surgery*; D007172:Erectile Dysfunction / Q000209:etiology* / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007431:Intraoperative Complications / Q000209:etiology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000627:therapeutic use; D009416:Nerve Regeneration / Q000187:drug effects; D010410:Penile Erection / Q000187:drug effects / Q000502:physiology; D010413:Penis / Q000098:blood supply / Q000294:innervation* / Q000601:surgery; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011468:Prostatectomy / Q000009:adverse effects* / Q000379:methods; D011471:Prostatic Neoplasms / Q000601:surgery; D011687:Purines; D011788:Quality of Life; D000068677:Sildenafil Citrate; D013450:Sulfones
D009414:Nerve Growth Factors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate